A Hopeful Leap Forward by Multicentric Cooperation for Precision-Based Therapy for Very Resistant, Relapsed, or Refractory Childhood Leukemia.
Journal
Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
entrez:
3
6
2021
pubmed:
4
6
2021
medline:
15
12
2021
Statut:
ppublish
Résumé
Pikman and colleagues report the results of a multicentric prospective clinical trial of the leukemia precision-based therapy (LEAP) consortium that combines identification of targetable lesions in drug-resistant childhood leukemia, tiered based on evidence for genomic lesions and drug target, validation of matching small-molecule targeted agents, and treatment of individual patients. The study demonstrates the impact of genomic information on disease classification, treatment guidance, and translational research, but also illustrates the challenges for target prediction and trial design for increasingly heterogeneous and smaller subgroups of patients.
Identifiants
pubmed: 34078660
pii: 11/6/1322
doi: 10.1158/2159-8290.CD-21-0258
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
1322-1323Commentaires et corrections
Type : CommentOn
Informations de copyright
©2021 American Association for Cancer Research.
Références
Pui C-H, Yang JJ, Hunger SP, Pieters R, Schrappe M, Biondi A, et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol. 2015;33:2938–48.
Sidhom I, Shaaban K, Youssef SH, Ali N, Gohar S, Rashed WM, et al. Reduced-intensity therapy for pediatric lymphoblastic leukemia: impact of residual disease early in remission induction. Blood. 2021;137:20–8.
Valent P, Orfao A, Kubicek S, Staber P, Haferlach T, Deininger M, et al. Precision medicine in hematology 2021: definitions, tools, perspectives, and open questions. Hemasphere. 2021;5:e536.
Wong M, Mayoh C, Lau LMS, Khuong-Quang D-A, Pinese M, Kumar A, et al. Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer. Nat Med. 2020;26:1742–53.
Pikman Y, Tasian SK, Sulis ML, Stevenson K, Blonquist TM, Apsel Winger B, et al. Matched targeted therapy for pediatric patients with relapsed, refractory, or high-risk leukemias: A report from the LEAP consortium. Cancer Discov. 2021;11:1424–39.
Gu Z, Churchman ML, Roberts KG, Moore I, Zhou X, Nakitandwe J, et al. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet. 2019;51:296–307.
Frismantas V, Dobay MP, Rinaldi A, Tchinda J, Dunn SH, Kunz J, et al. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood. 2017;129:e26–37.
Hahn WC, Bader JS, Braun TP, Califano A, Clemons PA, Druker BJ, et al. An expanded universe of cancer targets. Cell. 2021;184:1142–55.
Boehm JS, Garnett MJ, Adams DJ, Francies HE, Golub TR, Hahn WC, et al. Cancer research needs a better map. Nature. 2021;589:514–6.
Freireich EJ, Wiernik PH, Steensma DP. The leukemias: a half-century of discovery. J Clin Oncol. 2014;32:3463–9.